» Articles » PMID: 14588127

Attitudes to Prophylactic Surgery and Chemoprevention in Australian Women at Increased Risk for Breast Cancer

Overview
Date 2003 Nov 1
PMID 14588127
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Because of the uncertain efficacy of breast cancer screening in women at increased risk of developing breast cancer, bilateral prophylactic oophorectomy and mastectomy are considered management options for high-risk women. Data on the attitudes to prophylactic strategies of high-risk women who have not attended specialist clinics are needed to ascertain the need for patient education and provide the basis for planning of support services.

Methods: Three hundred seventy-one women unaffected by cancer and with unknown mutation status from families with a dominantly inherited susceptibility to breast cancer, recruited through a large Australian population-based, epidemiological study, were assessed using a mailed self-administered questionnaire with validated measures of psychological outcome.

Results: Sixteen percent of women reported considering prophylactic mastectomy, and 1% had already had the procedure. Among women with a family history of breast/ovarian cancer, 33% had considered and 5% had already had a prophylactic oophorectomy. Twenty-three percent of women reported considering taking tamoxifen if it were shown to prevent breast cancer. Consideration of prophylactic oophorectomy (OR = 1.51 for a 10% change in perceived risk, 95% CI 1.14-1.99, p = 0.0045) and tamoxifen (OR = 1.14 for a 10% change in perceived risk, 95% CI 1.002-1.30, p = 0.047) were positively associated with perceived cancer risk.

Conclusions: Attitudes to prophylactic surgery and psychological distress levels in high-risk women participating in an epidemiological study appear to be comparable to those of women attending familial cancer clinics and indicate that women attending high-risk clinics may be representative of the larger population of women at increased risk.

Citing Articles

Current and Emerging Strategies for Tubo-Ovarian Cancer Diagnostics.

Brincat M, Mira A, Lawrence A Diagnostics (Basel). 2023; 13(21).

PMID: 37958227 PMC: 10647517. DOI: 10.3390/diagnostics13213331.


Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.

Archer S, Fennell N, Colvin E, Laquindanum R, Mills M, Dennis R Cancers (Basel). 2022; 14(11).

PMID: 35681696 PMC: 9179465. DOI: 10.3390/cancers14112716.


Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review.

Meiser B, Wong W, Peate M, Julian-Reynier C, Kirk J, Mitchell G Hered Cancer Clin Pract. 2017; 15:14.

PMID: 28943990 PMC: 5607482. DOI: 10.1186/s13053-017-0075-8.


Decision making for breast cancer prevention among women at elevated risk.

Padamsee T, Wills C, Yee L, Paskett E Breast Cancer Res. 2017; 19(1):34.

PMID: 28340626 PMC: 5366153. DOI: 10.1186/s13058-017-0826-5.


Emotional and sexual concerns in women undergoing pelvic surgery and associated treatment for gynecologic cancer.

Stabile C, Gunn A, Sonoda Y, Carter J Transl Androl Urol. 2016; 4(2):169-85.

PMID: 26816823 PMC: 4708131. DOI: 10.3978/j.issn.2223-4683.2015.04.03.